- Home
- ELVN
as 04-18-2025 12:35pm EST
Enliven Therapeutics Inc is a clinical-stage precision oncology company focused on the discovery and development of potentially first-in-class precision oncology therapies. Enliven's programs are designed to address issues such as tolerability, combinability, resistance and disease escape through brain metastases. Its product candidates include ELVN-001 which is a potent, selective, small molecule kinase inhibitor designed to specifically target the BCR-ABL gene fusion, the oncogenic driver for patients with chronic myeloid leukemia, and the ELVN-002 which is central nervous system (CNS) penetrant and irreversible HER2 inhibitor with activity against wild type HER2 and various HER2 mutations.
| Founded: | 2016 | Country: | United States |
| Employees: | N/A | City: | BOULDER |
| Market Cap: | 1.1B | IPO Year: | 2020 |
| Target Price: | $39.25 | AVG Volume (30 days): | 359.8K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -1.89 | EPS Growth: | N/A |
| 52 Week Low/High: | $13.30 - $30.03 | Next Earning Date: | 05-13-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Stock Insider Trading Activity of Enliven Therapeutics Inc. (ELVN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Mar 27 '25 | Sell | $21.33 | 3,250 | $69,320.88 | 23,000 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Mar 24 '25 | Sell | $22.50 | 1,000 | $22,504.50 | 23,000 | |
| Lyssikatos Joseph P | ELVN | CHIEF SCIENTIFIC OFFICER | Mar 19 '25 | Sell | $20.61 | 12,500 | $257,575.00 | 1,002,688 | |
| Kintz Samuel | ELVN | PRESIDENT AND CEO | Mar 17 '25 | Sell | $20.83 | 12,500 | $260,320.00 | 990,392 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Mar 7 '25 | Sell | $21.44 | 6,667 | $142,936.48 | 323,310 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Feb 27 '25 | Sell | $20.41 | 3,250 | $66,326.98 | 23,000 | |
| Patel Anish | ELVN | CHIEF OPERATING OFFICER | Feb 6 '25 | Sell | $21.93 | 6,667 | $146,205.98 | 323,310 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Feb 5 '25 | Sell | $22.52 | 1,000 | $22,524.40 | 23,000 | |
| Hohl Benjamin | ELVN | CHIEF FINANCIAL OFFICER | Jan 27 '25 | Sell | $21.59 | 3,250 | $70,177.90 | 23,000 |
Latest Enliven Therapeutics Inc. News
ELVN Breaking Stock News: Dive into ELVN Ticker-Specific Updates for Smart Investing
PR Newswire
17 days ago
Enliven Therapeutics Announces Poster Presentations at the 2025 AACR Annual Meeting
PR Newswire
a month ago
Enliven Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides a Business Update
PR Newswire
2 months ago
Enliven Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Simply Wall St.
3 months ago
Enliven Therapeutics (NASDAQ:ELVN) Is In A Good Position To Deliver On Growth Plans
Yahoo Finance Video
3 months ago
Biotech walks a 'tightrope' amid unclear funding, regulations
MT Newswires
3 months ago
Enliven Therapeutics Insider Sold Shares Worth $685,868, According to a Recent SEC Filing
MT Newswires
4 months ago
BTIG Initiates Enliven Therapeutics at Buy With $42 Price Target
PR Newswire
5 months ago
Enliven Therapeutics Reports Third Quarter Financial Results and Provides a Business Update
Compare ELVN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ELVN Enliven Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.